Summary
Global Markets Direct’s, ‘Coronavirus Infection - Pipeline Review, H1 2016’, provides an overview of the Coronavirus Infection pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Coronavirus Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronavirus Infection and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Coronavirus Infection
- The report reviews pipeline therapeutics for Coronavirus Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Coronavirus Infection therapeutics and enlists all their major and minor projects
- The report assesses Coronavirus Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Coronavirus Infection
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Coronavirus Infection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coronavirus Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AstraZeneca Plc
Hemispherx Biopharma, Inc.
Humabs BioMed SA
Kineta, Inc.
NanoViricides, Inc.
Novavax, Inc.
Organic Vaccines
Phelix Therapeutics, LLC
Regeneron Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Coronavirus Infection Overview 7
Therapeutics Development 8
Pipeline Products for Coronavirus Infection - Overview 8
Pipeline Products for Coronavirus Infection - Comparative Analysis 9
Coronavirus Infection - Therapeutics under Development by Companies 10
Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 11
Coronavirus Infection - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Coronavirus Infection - Products under Development by Companies 15
Coronavirus Infection - Products under Investigation by Universities/Institutes 16
Coronavirus Infection - Companies Involved in Therapeutics Development 17
AstraZeneca Plc 17
Hemispherx Biopharma, Inc. 18
Humabs BioMed SA 19
Kineta, Inc. 20
NanoViricides, Inc. 21
Novavax, Inc. 22
Organic Vaccines 23
Phelix Therapeutics, LLC 24
Regeneron Pharmaceuticals, Inc. 25
Coronavirus Infection - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
coronavirus vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
coronavirus vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
FBR-001 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
interferon alfa-n3 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
interferon beta-1a - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LCA-60 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MERS-CoV Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Middle East respiratory syndrome vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Monoclonal Antibodies for Middle East Respiratory Syndrome - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Monoclonal Antibody for Coronavirus Infection - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SAB-301 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules for Viral Infections - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SSYA-10001 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Coronavirus Infection - Recent Pipeline Updates 53
Coronavirus Infection - Dormant Projects 58
Coronavirus Infection - Product Development Milestones 59
Featured News & Press Releases 59
Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome 59
Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62
List of Tables
Number of Products under Development for Coronavirus Infection, H1 2016 8
Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Comparative Analysis by Unknown Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Coronavirus Infection - Pipeline by AstraZeneca Plc, H1 2016 17
Coronavirus Infection - Pipeline by Hemispherx Biopharma, Inc., H1 2016 18
Coronavirus Infection - Pipeline by Humabs BioMed SA, H1 2016 19
Coronavirus Infection - Pipeline by Kineta, Inc., H1 2016 20
Coronavirus Infection - Pipeline by NanoViricides, Inc., H1 2016 21
Coronavirus Infection - Pipeline by Novavax, Inc., H1 2016 22
Coronavirus Infection - Pipeline by Organic Vaccines, H1 2016 23
Coronavirus Infection - Pipeline by Phelix Therapeutics, LLC, H1 2016 24
Coronavirus Infection - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Coronavirus Infection Therapeutics - Recent Pipeline Updates, H1 2016 53
Coronavirus Infection - Dormant Projects, H1 2016 58
List of Figures
Number of Products under Development for Coronavirus Infection, H1 2016 8
Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Targets, H1 2016 27
Number of Products by Stage and Targets, H1 2016 27
Number of Products by Mechanism of Actions, H1 2016 29
Number of Products by Stage and Mechanism of Actions, H1 2016 29
Number of Products by Routes of Administration, H1 2016 31
Number of Products by Stage and Routes of Administration, H1 2016 31
Number of Products by Molecule Types, H1 2016 33
Number of Products by Stage and Molecule Types, H1 2016 33
